retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Eli Lilly infiltrates anti-obesity market

Introduction Environmental factors including pollution, smoke, ultraviolet rays, and diet can cause damage to somatic cells due to the production of high amounts of reactive oxygen species (ROS)-mediated oxidative stress [ 1 ]

The assessment assists in determining the most appropriate therapies for obesity, obesity associated with comorbidities, obese diabetics and prevention of cardiac risks

Retatrutide at 12mg weekly produced 24.2% body weight loss in Phase 2 trials, which is the highest recorded for any single compound in obesity research

While improper use can cause temporary irritation, the skin heals readily once the irritant is removed